Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

FLT3 tyrosine kinase inhibitor (TKI) therapy evolved into a standard therapy in FLT3-mutated AML. TKI resistance, however, develops frequently with poor outcomes. We analyzed acquired TKI resistance in AML cell lines by multilayered proteome analyses. Leupaxin (LPXN), a regulator of cell migration a...

Descripción completa

Detalles Bibliográficos
Autores principales: Allert, Catana, Waclawiczek, Alexander, Zimmermann, Sarah Miriam Naomi, Göllner, Stefanie, Heid, Daniel, Janssen, Maike, Renders, Simon, Rohde, Christian, Bauer, Marcus, Bruckmann, Margarita, Zinz, Rafael, Pauli, Cornelius, Besenbeck, Birgit, Wickenhauser, Claudia, Trumpp, Andreas, Krijgsveld, Jeroen, Müller-Tidow, Carsten, Blank, Maximilian Felix
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522596/
https://www.ncbi.nlm.nih.gov/pubmed/36056084
http://dx.doi.org/10.1038/s41375-022-01687-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522596/
https://www.ncbi.nlm.nih.gov/pubmed/36056084
http://dx.doi.org/10.1038/s41375-022-01687-x

Ejemplares similares